Biocomposites exceeds revenue expectations and takes a big step forward in its research and development collaboration with Swiss innovator CSEM
- New record for sales growth and number of patients supported
- Product portfolio enhanced through acquisition of NanoBone® and expansion of STIMULAN® approval as an antibiotic carrier to treat bacterial infection
- Research and Development boosts with STIMULAN VG moving to phase II clinical trial and investment in Renovite
Keele, UK, 13 December 2023 – Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, reports a year of record growth, investment in new products and breakthroughs in research and development.
